Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development ...

The medication, Cobenfy, combines two drugs and is taken as a twice-daily pill. The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia ...

For people with schizophrenia, treatment is an ongoing, life-long process of antipsychotic medications and psychotherapy. Medications are key to controlling episodes, but most have serious enough side ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. The drug's journey from the lab through regulatory approval ...

The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after 70 years of incremental innovation that appears to avoid side effects that ...

MapLight Therapeutics, the second biotech to launch a Nasdaq bid this month, is a neuro-focused company advancing treatments ...

The U.S. Food and Drug Administration has approved a new drug for schizophrenia with a new mechanism of action for the first time in over 70 years. The treatment offers hope to thousands of patients ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...